Today’s Forbes Daily covers the booming peptide market, EU approves Paramount-Warner Bros. deal, Alphabet's earnings beat, a ...
Asianet Newsable on MSN
Missed AI, memory bull run? Biotech may be the next breakout trade — but retail sentiment has never been lower
Drugmakers have announced 37 biotech acquisitions worth at least $1 billion this year, topping the previous annual record.
19hon MSNOpinion
This workplace drug is surging — and it’s not what you expect
An Alarming Surge in Workplace Substance Use A shocking new study titled “Revealing the Unseen” exposes a significant rise in ...
If approved, ISL/LEN could become the first once-weekly, single-tablet HIV treatment to reach the market as patients rely on ...
Vermonters can now buy twice the amount of cannabis in a single day, after the state doubled the legal purchase limit to 2 ...
Mexican drug kingpin Ismael "El Mayo" Zambada will appear in court on Monday for sentencing in the U.S. to life in prison, ...
Eli Lilly's acquisition of psychedelic drug maker AtaiBeckley extends Big Pharma's embrace of a stigmatized class of ...
The FDA has approved Lipfendra, the first oral PCSK9 inhibitor, for the treatment of high cholesterol. Two medical experts explain why this matters.
An expanded federal library of chemical fingerprints helps scientists identify unknown substances found in forensic evidence, ...
Nationally, overdose deaths are falling. But not in Arizona. Source: Times analysis of C.D.C. data. Drug deaths in the U.S.
Biotech remains one of the market's more out-of-favor sectors despite improving industry fundamentals. Here are three stocks trading near multiyear lows.
PA marijuana licensing bill; Congressional bill on cannabis/drug testing in hospitals advances; MA psychedelics vote; Hemp & marijuana op-ed Your good deed for the day: donate to an independent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results